Revvity (RVTY) Q4 2025 Financial Results Summary

Revvity, Inc. (RVTY) Q4 2025 Financial Results Summary

Revvity, Inc. (NYSE: RVTY) reported its financial results for the fourth quarter and full year ended December 28, 2025, on February 2, 2026.

Fourth Quarter 2025 Highlights

• Revenue:
• $772 million, representing a 6% increase from $729 million in Q4 2024.

• Organic growth of 4% when adjusted for foreign exchange and acquisitions.

• Earnings Per Share (EPS):

• GAAP EPS was $0.87, up from $0.78 in Q4 2024 (a 11.6% increase).

• Adjusted EPS from continuing operations was $1.70, compared to $1.42 a year ago (an 19.8% increase).

• Operating Income:

• GAAP operating income from continuing operations was $112 million, down from $119 million in the previous year (a 5.9% decrease).

• GAAP operating profit margin decreased to 14.5% from 16.3% year-over-year.

• Adjusted Operating Income:

• Adjusted operating income was $229 million, slightly up from $221 million a year ago (a 3.6% increase).
• Adjusted operating profit margin was 29.7%, down from 30.3%.

Full Year 2025 Overview

• Revenue:

• Total revenue was $2.856 billion, compared to $2.755 billion in 2024 (a 3.7% increase).

• Earnings Per Share (EPS):

• GAAP EPS decreased to $2.07 from $2.20 in 2024 (a 5.9% decrease).

• Adjusted EPS from continuing operations improved to $5.06 from $4.90 (a 3.3% increase).

• Operating Income:

• GAAP operating income grew to $357 million from $347 million (a 2.9% increase).

• GAAP operating profit margin slightly decreased to 12.5% from 12.6%.

• Adjusted Operating Income:

• Adjusted operating income stood at $773 million, slightly down from $779 million (a 0.8% decrease).
• Adjusted operating profit margin decreased to 27.1% from 28.3%.

Segment Performance

Life Sciences

• Q4 2025:
• Revenue was $382 million, up from $375 million (a 2% increase).
• Adjusted operating income was $136 million, down from $138 million (a 1.4% decrease).

• Adjusted operating margin: 35.6%, down from 36.9%.

• Full Year 2025:

• Revenue was $1.431 billion, an increase from $1.399 billion (a 2% increase).
• Adjusted operating income was $458 million, down from $467 million (a 1.9% decrease).
• Adjusted operating margin: 32.0%, down from 33.4%.

Diagnostics

• Q4 2025:
• Revenue was $390 million, a 10% increase from $355 million.
• Adjusted operating income was stable at $91 million.

• Adjusted operating margin decreased to 23.4% from 25.7%.

• Full Year 2025:

• Revenue reached $1.425 billion, up from $1.356 billion (a 5% increase).
• Adjusted operating income decreased to $344 million from $354 million (a 2.8% decrease).
• Adjusted operating margin decreased to 24.2% from 26.1%.

Additional Information

• Dividends:

• The report indicated that dividends paid were $3.838 million in 2025, compared to $8.832 million in 2024.

• Share Repurchase:

• No share repurchase activity was disclosed in the report.

Guidance for 2026

Revvity has initiated its full-year guidance for 2026, projecting:
– Total revenue in the range of $2.96 billion to $2.99 billion, with organic revenue growth of 2-3%.
– Adjusted earnings per share expected between $5.35 and $5.45.

These financial results highlight Revvity’s continued growth trajectory despite facing some challenges in profitability margins. The strong performance in the diagnostics segment suggests a robust demand, potentially leveraging growth opportunities moving forward.